CD69 and cancer: The results showed that after HLB-apt treatment, T cell activation markers (CD69, CD3E), interleukin (IL-2), and other cytokines in Jurkat cells were significantly overexpressed (P<0.05) (Figure 5B), indicating an increase in Jurkat cell killing ability against cancer cells.